Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cohort study evaluating efficacy of bevacizumab plus paclitaxel in patients with HER2-negative inoperable or metastatic breast cancer (JBCRG-C05)

Next Previous
X
Search
Trial Profile

Cohort study evaluating efficacy of bevacizumab plus paclitaxel in patients with HER2-negative inoperable or metastatic breast cancer (JBCRG-C05)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 13 Aug 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Paclitaxel (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms B-SHARE
  • Sponsors Chugai Pharmaceutical

    • Most Recent Events

    • 21 Sep 2020 Results of pooled analysis from four studies (B-SHARE, ML21647, ML21165 and ML22452) presented at the 45th European Society for Medical Oncology Congress.
    • 04 Nov 2016 Planned End Date changed from 31 Oct 2017 to 30 Apr 2017.
    • 01 Oct 2014 Status changed from recruiting to active, no longer recruiting according to results presented at the Official 10th European Breast Cancer Conference.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top